{
    "organizations": [],
    "uuid": "24d5659e859d090a5f795abe3def97697f023629",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-athenex-announces-chinese-fda-allo/brief-athenex-announces-chinese-fda-allowance-of-investigational-new-drug-application-of-oraxol-to-begin-clinical-trials-idUSASB0C02Z",
    "ord_in_thread": 0,
    "title": "BRIEF-Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Athenex Inc:\n* ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS\n* ATHENEX INC - ACCEPTANCE OF ORAXOL IND BY CHINESE FDA ALLOWS ATHENEX TO COMMENCE A CLINICAL TRIAL PROGRAM FOR ORAXOL IN CHINA IN 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:16:00.000+02:00",
    "crawled": "2018-01-09T17:20:56.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "athenex",
        "inc",
        "athenex",
        "announces",
        "chinese",
        "fda",
        "allowance",
        "investigational",
        "new",
        "drug",
        "application",
        "oraxol",
        "begin",
        "clinical",
        "trial",
        "athenex",
        "inc",
        "acceptance",
        "oraxol",
        "ind",
        "chinese",
        "fda",
        "allows",
        "athenex",
        "commence",
        "clinical",
        "trial",
        "program",
        "oraxol",
        "china",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}